CL2004000498A1 - Polimorfo alpha, beta, gamma de rifaximina; procesos para la preparacion de dichos polimorfos; composicion farmaceutica que comprende dichos polimorfos, utiles como antibacterianos. - Google Patents

Polimorfo alpha, beta, gamma de rifaximina; procesos para la preparacion de dichos polimorfos; composicion farmaceutica que comprende dichos polimorfos, utiles como antibacterianos.

Info

Publication number
CL2004000498A1
CL2004000498A1 CL200400498A CL2004000498A CL2004000498A1 CL 2004000498 A1 CL2004000498 A1 CL 2004000498A1 CL 200400498 A CL200400498 A CL 200400498A CL 2004000498 A CL2004000498 A CL 2004000498A CL 2004000498 A1 CL2004000498 A1 CL 2004000498A1
Authority
CL
Chile
Prior art keywords
polymorphes
useful
rifaximina
rifaxymin
antibacterial
Prior art date
Application number
CL200400498A
Other languages
English (en)
Inventor
Giuseppe C. Viscomi
Manuela Campana
Dario Braga
Donatella Confortini
Vincenzo Cannata
Denis Severini
Paolo Righi
Goffredo Rosini
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33187382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2004000498(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Publication of CL2004000498A1 publication Critical patent/CL2004000498A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00—Heating by electric, magnetic or electromagnetic fields
    • H05B6/02—Induction heating
    • H05B6/10—Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12—Cooking devices
    • H05B6/1209—Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1236—Cooking devices induction cooking plates or the like and devices to be used in combination with them adapted to induce current in a coil to supply power to a device and electrical heating devices powered in this way
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00—Heating by electric, magnetic or electromagnetic fields
    • H05B6/02—Induction heating
    • H05B6/10—Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12—Cooking devices
    • H05B6/1209—Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1245—Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements
    • H05B6/1263—Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements using coil cooling arrangements

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Electromagnetism (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

FOMAS CRISTALINAS DEL ANTOBIOTICO RIFAXIMINA (INN) DENOMINADAS RIFAXIMINA a Y RIFAXIMINA b Y UNA FORMA POBREMENTE CRIATALINA DENOMINADA RIFAXIMINA y. ESTAS FORMAS SON DE UTILIDAD EN LA PRODUCCION DE PREPARACIONES MEDICINALES PARA USO POR VIA ORAL Y TOPICA Y SE PUEDE OBTENER POR MEDIO DE UN PROCESO DE CRISTALIZACION LLEVADO A CABO POR DISOLUCION EN CALIENTE DE LA RIFAXIMINA CRUDA EN ALCOHOL ETILICO Y POR CRISTALIZACION DEL PRODUCTO MEDIANTE LA ADICION DE AGUA A UNA TEMPERATURA DETERMINADA Y POR UN PERIODO DE TIEMPO DETERMINADO. LA CRISTALIZACION ES SEGUIDA DE UN SECADO LLVADO ACABO BAJO CONDICIONES CONTROLADAS HASTA ALCANZAR UN CONTENIDO DE AGUA ESPECIFICO EN EL PRODUCTO FINAL.
CL200400498A 2003-11-07 2004-03-11 Polimorfo alpha, beta, gamma de rifaximina; procesos para la preparacion de dichos polimorfos; composicion farmaceutica que comprende dichos polimorfos, utiles como antibacterianos. CL2004000498A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT002144A ITMI20032144A1 (it) 2003-11-07 2003-11-07 Forme polimorfe di rifaximina, processi per ottenerle e

Publications (1)

Publication Number Publication Date
CL2004000498A1 true CL2004000498A1 (es) 2005-03-11

Family

ID=33187382

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200400498A CL2004000498A1 (es) 2003-11-07 2004-03-11 Polimorfo alpha, beta, gamma de rifaximina; procesos para la preparacion de dichos polimorfos; composicion farmaceutica que comprende dichos polimorfos, utiles como antibacterianos.

Country Status (38)

Country Link
US (5) US7045620B2 (es)
EP (6) EP1676848B1 (es)
JP (5) JP2005139161A (es)
KR (4) KR20050043589A (es)
CN (4) CN1613858A (es)
AR (3) AR043547A1 (es)
AT (3) ATE421965T1 (es)
AU (2) AU2004200964A1 (es)
BR (2) BRPI0402382A (es)
CA (2) CA2460384A1 (es)
CL (1) CL2004000498A1 (es)
CO (1) CO5560083A1 (es)
CY (3) CY1108017T1 (es)
DE (4) DE602004006367C5 (es)
DK (3) DK1557421T3 (es)
ES (3) ES2320160T4 (es)
HK (3) HK1092151A1 (es)
HR (2) HRP20040265A2 (es)
IL (2) IL160798A0 (es)
IT (1) ITMI20032144A1 (es)
JO (1) JO2470B1 (es)
MA (1) MA27069A1 (es)
MD (1) MD3653G8 (es)
ME (1) ME00424B (es)
MX (2) MXPA04002353A (es)
NO (1) NO334950B1 (es)
NZ (1) NZ531622A (es)
PL (3) PL1676848T3 (es)
PT (3) PT1676847E (es)
RS (4) RS20060168A (es)
RU (1) RU2270200C2 (es)
SI (3) SI1676847T1 (es)
TN (2) TNSN04044A1 (es)
TW (1) TWI285107B (es)
UA (1) UA86384C2 (es)
WO (1) WO2005044823A2 (es)
YU (1) YU24804A (es)
ZA (1) ZA200401948B (es)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7902206B2 (en) * 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US7906542B2 (en) * 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20080262024A1 (en) * 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
US7923553B2 (en) * 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
ES2522895T3 (es) 2005-03-03 2014-11-19 Alfa Wassermann S.P.A. Nuevas formas polimorfas de rifaximina, procedimientos para su producción y uso de las mismas en preparados medicinales
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
AU2007281413B2 (en) 2006-08-02 2013-10-31 Christopher Jahraus Compositions and methods for the treatment of radiation proctosigmoiditis
ITMI20061692A1 (it) * 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
NZ575550A (en) * 2006-09-22 2011-12-22 Cipla Ltd Rifaximin
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
ITMI20071241A1 (it) * 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
PL2011486T5 (pl) * 2007-07-06 2016-09-30 Lupin Ltd Farmaceutyczne kompozycje rifaksyminy
AU2016203925B2 (en) * 2007-07-06 2016-10-20 Lupin Limited Pharmaceutical compositions of rifaximin
JP5755878B2 (ja) * 2007-07-06 2015-07-29 ルパン リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ リファキシミンの薬剤組成物
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
MY158257A (en) * 2008-02-25 2016-09-30 Salix Pharmaceuticals Ltd Forms of rifaximin and uses thereof
US8486956B2 (en) * 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
US11779571B2 (en) 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
DK2252148T3 (da) * 2008-02-26 2019-05-06 Salix Pharmaceuticals Ltd Fremgangsmåder til behandling af irritabel tarmsyndrom
WO2009137672A1 (en) 2008-05-07 2009-11-12 Salix Pharmaceuticals, Ltd. Methods of treating bowel disease by administering a bowel cleanser and an antibiotic
DK2327407T3 (da) 2008-09-26 2014-08-25 Aska Pharm Co Ltd Profylaktisk og/eller terapeutisk middel til funktionelle gastrointestinale sygdomme
US20100317681A1 (en) * 2009-06-15 2010-12-16 Salix Pharmaceuticals, Ltd. Modulation of systemic exposure to rifaximin
PL2350096T3 (pl) 2008-10-02 2020-06-29 Salix Pharmaceuticals, Ltd. Sposoby leczenia encefalopatii wątrobowej
US7928115B2 (en) * 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
KR101906177B1 (ko) 2008-12-10 2018-10-10 시플라 리미티드 리팍시민 복합체
IT1397617B1 (it) * 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina
CN102548408A (zh) * 2009-06-02 2012-07-04 萨利克斯药品有限公司 治疗肝性脑病的方法
EP2475392A4 (en) 2009-09-13 2013-01-09 Salix Pharmaceuticals Ltd METHOD FOR TREATING IRRITATION SYNDROME
CN102665693A (zh) * 2009-10-27 2012-09-12 鲁平有限公司 利福昔明固体分散体
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
JP2013511570A (ja) 2009-11-23 2013-04-04 シプラ・リミテッド 局所用泡沫組成物
EP2401282B2 (en) † 2009-12-28 2017-01-04 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
WO2011103246A1 (en) 2010-02-18 2011-08-25 Salix Pharmaceuticals, Ltd. Methods for treating infection
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
NZ603590A (en) * 2010-06-03 2015-08-28 Salix Pharmaceuticals Ltd New forms of rifaximin and uses thereof
WO2011156897A2 (en) * 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
SI2593463T1 (sl) 2010-07-12 2020-10-30 Salix Pharmaceuticals, Inc. Formulacije rifaksimina in njihove uporabe
WO2012035544A2 (en) 2010-09-13 2012-03-22 Sequent Scientific Ltd. A novel polymorphic form of rifaximin and process for its preparation
IT1403847B1 (it) * 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
WO2012060675A1 (es) * 2010-11-05 2012-05-10 Interquim, S.A. De C.V. Proceso para la preparación de rifaximina amorfa
WO2012076832A1 (en) * 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
AU2012214239B2 (en) * 2011-02-11 2016-06-30 Salix Pharmaceuticals, Ltd. Forms of Rifaximin and uses thereof
EP2705042A1 (en) 2011-05-02 2014-03-12 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
WO2012155981A1 (en) 2011-05-19 2012-11-22 Friulchem Spa New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby
ITMI20110890A1 (it) * 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
US20130184302A1 (en) * 2011-11-02 2013-07-18 Enoch Bortey Methods for treating irritable bowel syndrome (ibs) and infections
JP2013184902A (ja) * 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd リファキシミン含有結晶
WO2013185211A1 (en) * 2012-06-13 2013-12-19 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
WO2014091432A1 (en) 2012-12-12 2014-06-19 Ranbaxy Laboratories Limited Pharmaceutical compositions of rifaximin
WO2014140995A2 (en) 2013-03-15 2014-09-18 Alfa Wassermann S.P.A. Method for diagnosing vaginal infections
US20160038468A1 (en) 2013-03-15 2016-02-11 Alfa Wassermann S.P.A. Rifaximin for use in the treating of vaginal infections
CN105324109A (zh) 2013-04-12 2016-02-10 意大利阿尔法韦士曼制药公司 Nsaid施用和相关的组合物、方法和系统
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
EP2927235B1 (en) * 2014-03-31 2017-02-08 Euticals S.P.A. Polymorphic mixture of rifaximin and its use for the preparation of solid formulations
CA2946101A1 (en) * 2014-04-19 2015-10-22 Granules India Limited An improved process for the preparation of rifamycin derivatives
EP3140313B1 (en) 2014-05-04 2020-02-26 Salix Pharmaceuticals, Inc. Ibs microbiota and uses thereof
ES2810010T3 (es) 2014-05-12 2021-03-08 Alfasigma Spa Preparación y uso de la forma cristalina tau de rifaximina solvatada con DEGME
MX2016016458A (es) * 2014-06-30 2017-07-13 Salix Pharmaceuticals Inc Métodos para repetir tratamiento de síndrome del intestino irritable (ibs).
CN104083324B (zh) * 2014-07-10 2017-05-10 青岛动保国家工程技术研究中心有限公司 一种利福昔明的兽用悬乳剂及其制备方法和应用
EP2982764A1 (en) 2014-08-05 2016-02-10 ALFA WASSERMANN S.p.A. Identification of vaginal bacteria
CN104274391B (zh) * 2014-10-08 2017-02-01 哈尔滨坤盟医药科技有限公司 一种含利福昔明的药物制剂
WO2017021975A1 (en) * 2015-08-06 2017-02-09 Msn Laboratories Private Limited Process for the preparation of crystalline forms of rifaximin
EP3294270B1 (en) 2016-03-24 2018-09-12 Sandoz AG Pharmaceutical composition containing rifaximin alpha&delta
HUE044432T2 (hu) 2016-03-24 2019-10-28 Sandoz Ag Rifaximin alfá-t tartalmazó, hosszan eltartható kompozíció
US9988398B2 (en) * 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
EP4137132A1 (en) 2016-09-30 2023-02-22 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
CN106632396B (zh) * 2017-01-06 2019-01-11 成都樵枫科技发展有限公司 γ晶型利福昔明的制备方法和用途
PL3416627T3 (pl) * 2017-04-26 2020-06-01 Sandoz Ag Doustna postać dawkowania zawierająca rifaksyminę w postaci beta
EP3645539B1 (en) 2017-06-26 2021-04-07 Biofer S.p.A. Pyrido-imidazo rifamycin derivatives as antibacterial agent
WO2020245214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
BR112022003500A2 (pt) 2019-09-24 2022-05-24 Bausch Health Ireland Ltd Formulações líquidas de rifaximina
WO2021191312A1 (en) 2020-03-24 2021-09-30 Bausch Health Ireland Limited Methods of treating covid-19 with rifaximin
WO2021229480A1 (en) * 2020-05-15 2021-11-18 Atra Pharmaceuticals Limited Polymorph of rifaximin, process for the preparation thereof and pharmaceutical composition containing rifaximin
CN116018133A (zh) 2020-06-26 2023-04-25 博士医疗爱尔兰有限公司 靶向释放利福昔明组合物
WO2022090490A1 (en) 2020-10-29 2022-05-05 Bausch Health Ireland Limited Rifaximin liquid formulations for use in the treatment of sickle cell disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241785A (en) * 1978-07-24 1980-12-30 Peerless Of America, Inc. Heat exchangers and method of making same
IT1154655B (it) * 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) * 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
CA1215976A (en) 1984-05-15 1986-12-30 Vincenzo Cannata New process for the synthesis of imidazo rifamycins
IT1199413B (it) 1984-09-26 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
GB8816620D0 (en) * 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
EP0536197B1 (en) * 1990-06-29 1995-07-26 GRUPPO LEPETIT S.p.A. Pure crystalline form of rifapentine
US20020048610A1 (en) * 2000-01-07 2002-04-25 Cima Michael J. High-throughput formation, identification, and analysis of diverse solid-forms
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
CA2426393C (en) * 2000-10-31 2012-05-29 Ciba Specialty Chemicals Holding Inc. Crystalline forms of venlafaxine hydrochloride
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20050262269A1 (en) 2004-05-20 2005-11-24 Pike Jimmy D System and method for information handling system PCI express advanced switching
ES2522895T3 (es) 2005-03-03 2014-11-19 Alfa Wassermann S.P.A. Nuevas formas polimorfas de rifaximina, procedimientos para su producción y uso de las mismas en preparados medicinales
NZ575550A (en) * 2006-09-22 2011-12-22 Cipla Ltd Rifaximin
WO2008115572A1 (en) 2007-03-21 2008-09-25 Theraquest Biosciences, Inc. Methods and compositions of nsaids
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
PL2011486T5 (pl) 2007-07-06 2016-09-30 Lupin Ltd Farmaceutyczne kompozycje rifaksyminy
JP5755878B2 (ja) * 2007-07-06 2015-07-29 ルパン リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ リファキシミンの薬剤組成物
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
WO2009047801A1 (en) 2007-10-10 2009-04-16 Lupin Limited Therapeutic combinations and compositions for the treatment of gastrointestinal disorders
MY158257A (en) 2008-02-25 2016-09-30 Salix Pharmaceuticals Ltd Forms of rifaximin and uses thereof

Also Published As

Publication number Publication date
MD3653G8 (ro) 2016-08-31
US7915275B2 (en) 2011-03-29
US20080132530A1 (en) 2008-06-05
AR043547A1 (es) 2005-08-03
RU2004108953A (ru) 2005-10-27
DE602004006367D1 (de) 2007-06-21
KR20070113327A (ko) 2007-11-28
KR100883216B1 (ko) 2009-02-13
JP5635376B2 (ja) 2014-12-03
EP1682556A2 (en) 2006-07-26
BRPI0407149A8 (pt) 2019-01-15
MXPA06002644A (es) 2006-06-06
EP2208730A1 (en) 2010-07-21
ES2320160T3 (es) 2009-05-19
HRP20040265A2 (en) 2004-12-31
AR081991A2 (es) 2012-10-31
ES2320160T4 (es) 2011-03-09
IL174271A0 (en) 2006-08-01
RS54571B1 (en) 2016-06-30
US20120059023A1 (en) 2012-03-08
ME00424B (me) 2011-10-10
PL1557421T3 (pl) 2007-08-31
HK1073657A1 (en) 2005-10-14
CN101260114A (zh) 2008-09-10
ES2244364T1 (es) 2005-12-16
PT1557421E (pt) 2007-07-31
CN1613858A (zh) 2005-05-11
UA86384C2 (uk) 2009-04-27
ES2320161T3 (es) 2009-05-19
IL160798A0 (en) 2004-08-31
EP1676847A1 (en) 2006-07-05
PT1676848E (pt) 2009-04-09
JP2014177500A (ja) 2014-09-25
PL1676847T3 (pl) 2009-07-31
EP1676847B1 (en) 2009-01-28
CN101260115A (zh) 2008-09-10
KR20060110737A (ko) 2006-10-25
EP1557421B1 (en) 2007-05-09
CN1886408A (zh) 2006-12-27
MD20060080A (en) 2006-11-30
CO5560083A1 (es) 2005-09-30
NZ531622A (en) 2004-10-29
TNSN06069A1 (en) 2007-10-03
HRP20060093B1 (hr) 2015-12-18
CY1108017T1 (el) 2013-09-04
CN101260114B (zh) 2012-11-28
AR081992A2 (es) 2012-10-31
TNSN04044A1 (en) 2006-06-01
CY1108964T1 (el) 2014-07-02
KR20070113326A (ko) 2007-11-28
HK1092151A1 (en) 2007-02-02
CN1886408B (zh) 2010-06-09
EP1557421A1 (en) 2005-07-27
ITMI20032144A1 (it) 2005-05-08
JP5199576B2 (ja) 2013-05-15
ATE421965T1 (de) 2009-02-15
TW200515913A (en) 2005-05-16
US8173801B2 (en) 2012-05-08
US7045620B2 (en) 2006-05-16
CA2460384A1 (en) 2005-05-07
RS20150291A1 (en) 2015-10-30
US20110160449A1 (en) 2011-06-30
SI1557421T1 (sl) 2007-08-31
ATE421966T1 (de) 2009-02-15
DK1676847T3 (da) 2009-05-11
IL174271A (en) 2010-12-30
DK1557421T3 (da) 2007-09-17
WO2005044823A2 (en) 2005-05-19
JP2011046738A (ja) 2011-03-10
BRPI0402382A (pt) 2005-06-28
ES2244364T3 (es) 2007-12-01
JP2007509904A (ja) 2007-04-19
SI1676848T1 (sl) 2009-06-30
ZA200401948B (en) 2004-04-29
AU2004287601B8 (en) 2009-03-05
CA2538546A1 (en) 2005-05-19
DE602004006367C5 (de) 2019-04-04
RU2270200C2 (ru) 2006-02-20
DE04005541T1 (de) 2005-12-29
BRPI0407149A (pt) 2006-02-07
PT1676847E (pt) 2009-04-09
DK1676848T3 (da) 2009-05-11
EP1676848A1 (en) 2006-07-05
SI1676847T1 (sl) 2009-06-30
CY1108909T1 (el) 2014-07-02
HK1092150A1 (en) 2007-02-02
MXPA04002353A (es) 2005-05-11
US8404704B2 (en) 2013-03-26
YU24804A (sh) 2006-08-17
NO20061110L (no) 2006-04-19
AU2004287601B2 (en) 2009-02-26
AU2004200964A1 (en) 2005-05-26
JP2011057698A (ja) 2011-03-24
AU2004287601A1 (en) 2005-05-19
DE602004019298D1 (de) 2009-03-19
JO2470B1 (en) 2009-01-20
KR100855084B1 (ko) 2008-08-29
US20050272754A1 (en) 2005-12-08
ATE361927T1 (de) 2007-06-15
KR20050043589A (ko) 2005-05-11
RS54568B1 (en) 2016-06-30
US20050101598A1 (en) 2005-05-12
EP2210893A1 (en) 2010-07-28
RS20060168A (en) 2008-09-29
PL1676848T3 (pl) 2009-07-31
WO2005044823A3 (en) 2005-10-27
RS54569B1 (en) 2016-06-30
MA27069A1 (fr) 2004-12-20
CA2538546C (en) 2011-04-19
MD3653F2 (en) 2008-07-31
RS20150292A1 (en) 2015-10-30
NO334950B1 (no) 2014-08-04
DE602004006367T2 (de) 2007-09-06
HRP20060093A2 (en) 2006-05-31
CN101260115B (zh) 2011-11-23
JP2005139161A (ja) 2005-06-02
KR100867751B1 (ko) 2008-11-10
DE602004019296D1 (de) 2009-03-19
EP1676848B1 (en) 2009-01-28
TWI285107B (en) 2007-08-11

Similar Documents

Publication Publication Date Title
CL2004000498A1 (es) Polimorfo alpha, beta, gamma de rifaximina; procesos para la preparacion de dichos polimorfos; composicion farmaceutica que comprende dichos polimorfos, utiles como antibacterianos.
AR109797A2 (es) Formas de dosificación farmacéutica
TNSN07292A1 (en) New polymorphous forms of rifaximin,processes for their production and use thereof in the medicinal
CR20200532A (es) Compuestos de heteroarilo tetracíclicos
AR106561A2 (es) Composición farmacéutica que contiene un ácido tetrahidrofólico
DOP2010000259A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211
ATE557013T1 (de) Glucopyranosyl-substituierte benzol-derivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
UY29377A1 (es) Nuevas formilaciones líquidas de rotavirus, su preparación y sus usos.
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
PL1750700T3 (pl) Ciekły preparat dla medycyny weterynaryjnej; sposób jego wytwarzania i zastosowanie
NZ606194A (en) Isoxazoline derivatives as antiparasitic agents
CL2009002206A1 (es) Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
UY29384A1 (es) Derivados del ácido2-3s,4r)-4-(((3,4-dicloro-5-metil-1h-pirrol-2-il) carbonil)amino)-1,3-tiazol-5-carboxílico y sus sales, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciónes.
AR037654A1 (es) Base libre de clindamicina sustancialmente cristalina, sustancia droga, composicion farmaceutica y su uso en la fabricacion de un medicamento y proceso para preparar dicha base libre cristalina de clindamicina
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
UY32673A (es) Nuevas pirimidinas, composiciones farmaceuticas que las contienen, procedimientos de preparaciones y su aplicacion como medicamentos
UY31864A (es) Derivados de urea hetericíclica y métodos de uso de los mismos-332
CO2020002904A2 (es) Fabricación de composiciones farmacéuticas
UY32856A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
CL2009001342A1 (es) Pregn-4-en-21,17-carbolactonas sustituidas en el anillo c; preparados farmaceuticos que lo contienen; compuesto 11 alfa-hidroxi-15 beta, 16 beta-metilen-androst-4-en-3,17-diona; procedimiento para preparar dicho compuesto que comprende el uso de microorganismos.
UY30121A1 (es) Nuevos compuestos
MD228Z (ro) Procedeu de cultivare a cianobacteriei Spirulina platensis
GB0615105D0 (en) Novel compounds
CL2018003739A1 (es) Formas cristalinas de un compuesto de tetraciclina sustituida con 9-aminometilo y un método para su preparación.
UY26211A1 (es) Polimorfos de un diclorhidrato cristalino de azobiciclo (2.2.2)oct-3-ilamina y sus composiciones farmaceuticas